Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Archived Monthly Oncology Tumor Boards: Treatment of Deficient Mismatch Repair or Microsatellite Instability-High (dMMR/MSI-H) Colorectal Cancer
As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Evidence-Based Guidance on New Paradigms in the Treatment of Acute Myeloid Leukemia
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments
Ampullary adenocarcinoma is frequently grouped with biliary tract and pancreatic cancers due to its low prevalence. Because of its rarity, it is not a well-known or studied cancer in the community. Systemic therapies used to treat ampullary adenocarcinoma are complex and pharmacists play an important role in managing treatment, toxicity, and supportive care measures.
Category
  • Ampullary Adenocarcinoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Plenary Session: Best Practices for Addressing the Health Needs of the LGBTQ+ Community in Oncology Care
In 2022, NCCN conducted a patient advocacy scan with roughly a dozen representatives from the LGBTQ+ community representing patient advocates, researchers, and healthcare providers with expertise in this area. The results of the scan found that patients who are LGBTQ+ are likely to report experiencing bias and discrimination in care which can impact their care outcomes.
Category
  • Disparities
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 ASWB continuing education credit
  • 1.50 Participation
Cancer Screening in Underrepresented Populations
All individuals, regardless of their race, socioeconomic status, or gender identity deserve the best chance at beating cancer.
Category
  • Disparities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Mobile Screening Programs: Improving Patient Access to Oncology Care
It is important for cancer centers that are interested in developing mobile screening programs at their respective institutions to be informed about issues and challenges experienced in the development of successful mobile screening programs.
Category
  • Disparities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages